-
HutchMed’s Elunate-Tyvyt Combo Receives Breakthrough Therapy Designation in China for Endometrial Cancer
•
HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) has announced that the combination of Elunate (fruquintinib) and Tyvyt (sintilimab) has been granted Breakthrough Therapy Designation (BTD) in China for the treatment of patients with mismatch repair normal (pMMR) advanced endometrial cancer. These patients have previously failed at least one line of…
-
Kintor Pharmaceutical Initiates Long-Term Safety Trial for Androgenetic Alopecia Treatment KX-826
•
China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced the start of the long-term safety trial for KX-826, a potential first-in-class androgen receptor (AR) antagonist for the treatment of androgenetic alopecia (AGA). This in-house developed treatment has completed its first patient enrollment in China. Phase III Clinical Trial Design and ObjectivesThe…
-
Hybribio Ltd and United Imaging Healthcare Form Strategic Partnership to Advance Medical Technology
•
Guangdong-based Hybribio Ltd (SHE: 300639), a leading provider of nucleic acid molecular diagnostic products, has entered into a partnership with Shanghai-headquartered medical imaging company United Imaging Healthcare (UIH, SHA: 688271). The collaboration aims to harness the power of advanced medical intelligent technologies to enhance medical services. Integrating AI and Nuclear…
-
Novomics Partners with TopGene to Expand Genomic Testing Services in China
•
South Korea-based molecular diagnostics firm Novomics Co. has announced a strategic partnership with China-based Hubei TopGene Biotechnology Co., Ltd to extend its presence in the Chinese market. Under this collaboration, TopGene will facilitate access to Novomics’ genomic testing services, including diagnostic kits and genetic information consulting, specifically for Chinese gastric…
-
Stemirna Therapeutics Halts mRNA Vaccine Factory Construction Amid Low Demand
•
China-based Stemirna Therapeutics Co., Ltd has decided to halt the construction of a factory intended for the manufacturing of its mRNA-based COVID-19 vaccine. This decision comes in response to an anticipated lack of sufficient market demand. According to a Reuters report, Stemirna had initiated testing production at the site but…
-
BGI Genomics Partners with Thai Entities to Combat Thalassemia through Genomics and Cell Therapy
•
China-based genomics leader BGI Genomics Co., Ltd (SHE: 300676) has entered into a memorandum of understanding (MOU) with Thailand’s Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok Genomics Innovation Public Company Limited, and Hemogen Hongkong Alpha Technology., Ltd. The collaboration aims to enhance the prevention and treatment of Thalassemia and…
-
Shanghai Junshi Biosciences’ Tuoyi Receives NMPA Review for ES-SCLC Treatment
•
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced that the National Medical Products Administration (NMPA) has accepted its filing for an additional indication of Tuoyi (toripalimab). The drug is proposed to be used in combination with etoposide and platinum for the treatment of extensive stage small cell…
-
Sichuan Gowell Pharmaceutical Wins Reversal in Forxiga Patent Infringement Case
•
Sichuan Gowell Pharmaceutical Co., Ltd. has secured a favorable final judgment in its appeal against the assertion that its generic version of AstraZeneca’s (AZ, NASDAQ: AZN) type 2 diabetes therapy, Forxiga (dapagliflozin), infringed upon a patent listed by AstraZeneca on the Center for Drug Evaluation (CDE)’s drug patent registration platform,…
